Aclarion Inc. (Nasdaq: ACON, ACONW), the Broomfield healthcare technology company focused on chronic low back pain, announced an update on its improved positioning following successful strategic initiatives in the first quarter of 2025. The company raised over $20 million in Q1, maintaining nearly $15 million in cash on hand. Aclarion reported a clean capital structure,…more
Aclarion Inc. (NASDAQ: ACON, ACONW) announced a 1-for-27 reverse stock split of its common stock, effective before market open on March 28. On Sept. 23, 2024, the Broomfield-based company’s stockholders approved an amendment to the company’s Certificate of Incorporation to authorize a reverse stock split with the ratio set by its Board of Directors. The…more
Terumo Blood and Cell Technologies (Terumo BCT) has signed a memorandum of understanding (MOU) with the Osong Medical Innovation Foundation (KBIOHealth) to jointly develop workforce training for cell and gene therapy (CGT) manufacturing. The partnership aims to create training programs focused on mesenchymal stem cell (MSC) and chimeric antigen (CAR) T-cell therapies, utilizing Terumo BCT’s…more
Aclarion Inc. (Nasdaq: ACON, ACONW), the healthcare technology company based in Broomfield, plans expand Nociscan access across key markets in New York and New Jersey. This expansion builds on previously established Nociscan sites with RadNet affiliates in both states and is driven by the increased availability of MR Spectroscopy (MRS) and enhanced remote operations capabilities…more
Aclarion Inc. has established a commercial agreement with Scripps Health in San Diego, Calif., expanding access to its Nociscan technology for spine physicians and more than 3.2 million residents in the greater San Diego area. The Nociscan technology utilizes MR Spectroscopy (MRS) and Augmented Intelligence to identify sources of chronic low back pain. Scripps Health…more
Terumo Blood and Cell Technologies (Terumo BCT) has partnered with the nonprofit National Alliance of Sickle Cell Centers (NASCC), which is focused on improving the lives of individuals with sickle cell disease (SCD). The collaboration, titled BET on Blood for SCD, aims to enhance access to blood transfusion therapy and educate healthcare providers on its…more
Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield healthcare technology company, has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its 24th issued US patent. This new patent expands Aclarion’s proprietary rights to utilize magnetic resonance spectroscopy (MRS) to measure propionic acid (PA) as a biomarker for identifying potential…more
Aclarion Inc. (Nasdaq: ACON, ACONW), a Broomfield health care technology company, has named Northwestern Medicine as the initial site for its CLARITY trial. This study is aimed at demonstrating the clinical and economic value of Nociscan in spine surgery, particularly for chronic low back pain. The CLARITY trial is a randomized study designed to show…more
Aclarion Inc. (Nasdaq: ACON, ACONW) has secured nearly $20 million in gross proceeds since Jan. 1, 2025, which fully funds its pivotal CLARITY trial. The trial is designed to demonstrate the clinical and economic value of Nociscan in spine surgery. Ryan Bond, chief strategy officer of Broomfield-based Aclarion, said, “This milestone ensures we reach the…more
Terumo Blood and Cell Technologies (Terumo BCT) announced today that Carter BloodCare is the first U.S. adopter of its Reveos Automated Blood Processing System and Lumia Software Platform. This implementation aims to meet the needs of Texas patients for platelets, plasma and red blood cells. Carter BloodCare, one of the largest blood centers in Texas,…more
Osteotec has announced an exclusive distribution agreement with Westminster-based Highridge Medical to distribute spine surgery solutions in the UK. The partnership, effective Dec. 13, 2024, combines Osteotec’s established presence in the UK with Highridge Medical’s spinal products. This move aims to strengthen Osteotec’s spine product portfolio and enhance opportunities for both patient outcomes and market…more
Terumo Blood and Cell Technologies (Terumo BCT) and FUJIFILM Irvine Scientific will collaborate to accelerate T cell expansion for cell therapy developers. The partnership focuses on using Fujifilm’s PRIME-XV T Cell Expansion Media in conjunction with Terumo BCT’s Quantum Flex Cell Expansion System. This collaboration aims to simplify and scale T cell expansion processes, reducing…more